Experimental Alzheimer’s drug shows potential despite failure in trials

An experimental Alzheimer’s drug called solanezumab did not show benefits in two recent Phase 3 clinical trials, but the treatment did show some potential to help, researchers said. The drug failed in individual studies of about 1,000 participants each, but researchers saw a slowing of cognitive decline when they combined the data from the two trials. They also saw a statistically significant benefit when they examined only patients with mild cases of Alzheimer’s.
Read the article >>
Find out more about clinical trials >>